We are live on ! Find out more
PACB icon

Pacific Biosciences

160 hedge funds and large institutions have $873M invested in Pacific Biosciences in 2019 Q1 according to their latest regulatory filings, with 29 funds opening new positions, 65 increasing their positions, 41 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

59% more repeat investments, than reductions

Existing positions increased: 65 | Existing positions reduced: 41

33% more funds holding in top 10

Funds holding in top 10: 34 (+1)

26% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 23

8% more capital invested

Capital invested by funds: $809M → $873M (+$63.2M)

6.85% more ownership

Funds ownership: 73.1%79.95% (+6.9%)

3% more funds holding

Funds holding: 155160 (+5)

73% less call options, than puts

Call options by funds: $1.19M | Put options by funds: $4.36M

Holders
160
Holders Change
+5
Holders Change %
+3.23%
% of All Funds
3.46%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.09%
New
29
Increased
65
Reduced
41
Closed
23
Calls
$1.19M
Puts
$4.36M
Net Calls
-$3.17M
Net Calls Change
-$7.29M
Name Holding Trade Value Shares
Change
Change in
Stake
HS
51
HighVista Strategies
Massachusetts
$2.74M +$2.74M +378,479 New
Ohio Public Employees Retirement System (OPERS)
52
Ohio Public Employees Retirement System (OPERS)
Ohio
$2.69M
Barclays
53
Barclays
United Kingdom
$2.57M -$1.76M -243,122 -41%
BLAM
54
Bourne Lent Asset Management
New York
$2.43M
CS
55
Candriam SCA
Luxembourg
$2.4M +$318K +44,000 +15%
TA
56
Teachers Advisors
New York
$2.38M +$78.2K +10,807 +3%
MOACM
57
Mutual of America Capital Management
New York
$2.31M -$5.36K -741 -0.2%
BPGAM
58
BTG Pactual Global Asset Management
Bermuda
$2.21M +$1.1M +152,166 +99%
BCM
59
Bridgeway Capital Management
Texas
$2.21M
State of Wisconsin Investment Board
60
State of Wisconsin Investment Board
Wisconsin
$2.17M
Walleye Trading
61
Walleye Trading
New York
$2.1M +$452K +62,496 +27%
Ameriprise
62
Ameriprise
Minnesota
$2.09M +$1.25M +173,366 +149%
PWPCM
63
Perella Weinberg Partners Capital Management
New York
$2.08M -$122K -16,827 -6%
Capstone Investment Advisors
64
Capstone Investment Advisors
New York
$1.79M -$2.68M -370,579 -60%
Swiss National Bank
65
Swiss National Bank
Switzerland
$1.77M +$85.3K +11,800 +5%
Squarepoint
66
Squarepoint
New York
$1.74M -$182K -25,174 -9%
TCIM
67
TIAA CREF Investment Management
New York
$1.64M +$4.85K +670 +0.3%
Morgan Stanley
68
Morgan Stanley
New York
$1.63M -$582K -80,464 -26%
PP
69
Paloma Partners
Connecticut
$1.62M +$500K +69,200 +45%
PAM
70
Panagora Asset Management
Massachusetts
$1.55M -$711K -98,308 -31%
California State Teachers Retirement System (CalSTRS)
71
California State Teachers Retirement System (CalSTRS)
California
$1.53M -$18.4K -2,540 -1%
AC
72
Athos Capital
Hong Kong
$1.5M +$967K +133,666 +186%
PPA
73
Parametric Portfolio Associates
Washington
$1.38M -$386K -53,337 -22%
MS
74
Maven Securities
Jersey
$1.33M +$870K +120,254 +189%
Public Sector Pension Investment Board (PSP Investments)
75
Public Sector Pension Investment Board (PSP Investments)
Quebec, Canada
$1.32M +$691K +95,600 +110%

PACB Hedge Fund Activity: Q1 2019 in Review

160 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Pacific Biosciences (PACB) for Q1 2019, worth a combined $873M — up 7.8% from $809M a quarter earlier.

Buyers outnumbered sellers: 29 funds opened new PACB positions and 23 closed out — a net gain of 6 holders — while 65 added to existing stakes and 41 trimmed.

The largest buyer was UBS O'Connor, adding an estimated $22.2M. The largest seller was Consonance Capital Management, exiting entirely with an estimated $18.2M sold.

  • 160 institutional investors held Pacific Biosciences (PACB) as of Q1 2019, up from 155 in Q4 2018.
  • Funds reported $873M of Pacific Biosciences stock for Q1 2019, up 7.8% quarter-over-quarter.
  • 29 funds opened new Pacific Biosciences positions in Q1 2019 and 23 closed out, a net change of +6 holders.
  • The largest Pacific Biosciences buyer in Q1 2019 was UBS O'Connor, an estimated $22.2M added.
  • The largest Pacific Biosciences seller in Q1 2019 was Consonance Capital Management, an estimated $18.2M sold.

Based on aggregated 13F filings for Q1 2019.